ADA 2019 – Provention claims success where Lilly failed
The company’s teplizumab delays development of type 1 diabetes, but Lilly’s failure with the same project nine years earlier casts a long shadow.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.